- Biosimilars – Now a reality even for complex biologics
Biosimilars – Now a reality even for complex biologics
Tuesday 20 June 2017
Biosimilars: now a reality, even for complex biologics
Biosimilars have been a hot topic among healthcare investors for a few years now and should further take center stage over the next five years as eight out the Top 10 bestselling therapies worldwide will face biosimilar competition. Starting late but having all the relevant expertise and production know-how Biotech companies have partnered with large Pharmaceutical groups to develop biosimilars. While the BPCI Act within Obamacare set a regulatory framework for biosimilars to be approved by the US FDA, its different provisions had first to be battled in court for the law to take shape. This is now almost done.
This Month's Topic - The euro’s appreciation: causes, outlook and consequences
This Month's topicThe euro remains undervalued according to the majority of valuation models and is boosted by a domestic economy that has strengthened considerably since the beginning of the year. It is not the euro’s value that is a surprise, but the speed at which the currency has appreciated since early May.
Global Investment Views - 09-2017
CIO views: High conviction ideas from Amundi Global Investment Committee
Discussion paper : Opportunities of deep-sea mining and ESG risks
Discussion paper In recent decades, interest in deep-sea mining has been growing, focusing mainly on three types of deposits: polymetallic nodules, polymetallic sulphides and cobalt-rich crusts. These deposits could contain large amounts of minerals, making them an interesting option to meet growing global demand.